查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1803870

非鸦片类药物治疗市场（依药物类型、给药途径、应用、最终用途和分销管道）－2025-2030 年全球预测

Non-Opioid Therapeutics Market by Drug Type, Route of Administration, Application, End Use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

非鸦片类药物治疗市场预计到 2024 年将达到 407.7 亿美元，2025 年将达到 437.8 亿美元，到 2030 年将达到 629 亿美元，复合年增长率为 7.49%。

主要市场统计数据
基准年2024年 407.7亿美元
预计2025年 437.8亿美元
预测年份 2030 629亿美元
复合年增长率（%） 7.49%

透过先进的分子标靶、以患者为中心的解决方案和协作创新改变疼痛管理，开启非阿片类药物治疗的新时代

随着非鸦片类药物疗法成为医学创新的前沿，疼痛管理的改变正发生根本性转变。这种快速成长的驱动力源自于尖端分子研究、以病人为中心的照护模式以及注重安全性和有效性的全球法规环境。透过摆脱传统的鸦片类药物依赖，该行业正在为有望降低成瘾风险并保持可靠临床疗效的新型治疗方法铺平道路。

揭示了透过新模式、监管调整和数位健康整合重新定义非阿片类药物治疗格局的变革性变化

目前的非鸦片类药物治疗格局正因变革性转变而再形成，这些变革包括新模式、监管调整和技术整合。例如，新一代离子通道调变器和胜肽类疗法的兴起正在重新定义药理套件。同时，主要市场的监管机构已发布更新指南，简化了那些与管制药物相比具有良好安全边际的治疗方法的加速核准。

全面分析2025年美国关税对非鸦片类药物供应链、定价结构与全球贸易动态的影响

2025年美国关税的实施，给支持非阿片类药物研发和分销的全球供应链带来了巨大压力。依赖进口原料药的製造商面临采购成本上升的困境，这促使他们重新评估其供应商关係和近岸外包策略。为此，一些中型製造商已启动在地采购协议，以确保业务的连续性和成本的可预测性。

透过药物类型、给药途径、临床用途、最终用途和分销管道等关键见解，绘製非鸦片类药物治疗市场格局

透过按药物类型细分，我们发现对乙酰胺酚衍生物仍然是急性疼痛缓解的基石，而抗忧郁症机制的进展正在揭示慢性疼痛缓解的新途径。与抗癫痫药物的发展同步，神经病变疼痛管理的应用也有望得到推广，局部麻醉剂的创新也正在增强手术全期护理。新一代非类固醇消炎剂的配方提高了胃肠道耐受性，并将继续广泛应用于各种发炎疾病。

探索美洲、中东和非洲以及亚太地区的区域动态，这些动态将影响市场渗透、患者获取和成长机会

在美洲，监管机构正在协调核准流程，核准具有非成瘾性的疗法，培育强大的临床研发管线，并吸引创业投资。医疗保健报销模式正日益包容非阿片类药物替代品，患者权益组织正在影响政策，以扩大创新治疗方法的可及性。这一区域性势头正在加速产品上市，并为综合疼痛管理试验计画创造肥沃的土壤。

与领先的行业参与者建立创新伙伴关係，推动非阿片类药物治疗领域的研发和商业化

业界领导企业正在采取多管齐下的策略，以保持其在非鸦片类药物治疗领域的竞争优势。拥有强大研发实力的全球製药公司正在透过内部药物发现专案和定向收购生物技术创新公司来扩大其产品组合。同时，非阿片类药物专家正在与学术中心和受託研究机构建立伙伴关係，以加速转化研究。

为产业领导者提供策略性和可操作性的建议，以加强合作、加速创新并应对非鸦片类药物治疗领域的监管复杂性

产业领导者应优先建立策略联盟，将学术研究与商业开发连接起来，以加速研发管线的推进。透过利用共用的专业知识和资源池，各组织可以降低早期风险并加强候选药物的检验。同时，组成联盟倡导统一的监管标准，可以简化核准途径并加快上市时间。

市场分析所依据的全面二手资料调查方法的详细信息，包括初步访谈、二手资料检验和专家小组评审

分析基于稳健的多元调查方法，结合了一手资料和二手资讯来源。一手资料研究包括对製药、生物技术和医疗保健提供者高阶主管的深入访谈，以及与监管专家和关键意见领袖的对话，以检验新兴趋势和策略重点。

结论强调了非鸦片类药物疗法在满足未满足需求、推动永续成长和改​​善全球患者治疗效果方面的变革潜力

非鸦片类药物治疗的普及之路以技术创新、策略合作和不断变化的监管格局为特征。随着相关人员围绕着通用目标——降低阿片类药物成瘾——携手合作，该领域正经历着新型分子实体、数位健康整合和以患者为中心的医疗模式的空前繁荣。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 利用下一代脂质体递送系统控制局部疼痛的新兴局部抗发炎製剂
  • 拓展新型钠通道阻断剂用于治疗老年人慢性神经病变疼痛
  • 加速监管核准，促进用于缓解术后疼痛的新型胆囊收缩素受体调节剂的开发
  • 虚拟实境与数位疗法在復健环境中的非鸦片类镇痛治疗的应用
  • 利用基于转录组的生物标记实现非阿片类镇痛治疗的个人化并改善临床疗效
  • 增加针对神经生长因子的单株抗体的投资，用于治疗骨关节炎和背痛
  • 生技公司与数位医疗公司建立策略伙伴关係，加速非鸦片类疼痛管理解决方案的开发

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 非鸦片类治疗药物市场（依药物类型）

  • 乙酰胺酚
  • 抗忧郁症
  • 抗癫痫药物
  • 局部麻醉剂
  • 非类固醇消炎剂

9. 非鸦片类药物治疗市场（依给药途径）

  • 静脉
  • 口服
  • 直肠

第十章非鸦片类药物治疗市场（依应用）

  • 癌症相关疼痛
  • 慢性疼痛
  • 发炎性疾病
  • 偏头痛
  • 神经退化性疾病

11. 非鸦片类药物治疗市场（依最终用途）

  • 门诊手术中心
  • 诊断中心
  • 居家照护环境
  • 医院和诊所

第 12 章非鸦片类药物治疗市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

13.美洲非阿片类药物治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲非鸦片类药物治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区非鸦片类药物治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • GlaxoSmithKline plc
    • Acorda Therapeutics, Inc.
    • Allay Therapeutics Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Biogen Inc.
    • Centrexion Therapeutics,
    • Concentric Analgesics, Inc.
    • Confo Therapeutics NV
    • Durect Corporation
    • Eli Lilly and Company
    • Latigo Biotherapeutics, Inc.
    • Lexicon Pharmaceuticals, Inc.
    • Liquidia Corporation
    • McNeil-PPC, Inc. by Johnson & Johnson Inc.
    • Mylan NV by Viatris Inc.
    • Neumentum Inc.
    • SiteOne Therapeutics, Inc.
    • Sun Pharmaceutical Industries Limited
    • Tris Pharma, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • Amgen Inc.
    • Cara Therapeutics, Inc.
    • Bioelectronics Corporation

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-4772A753AA73

The Non-Opioid Therapeutics Market was valued at USD 40.77 billion in 2024 and is projected to grow to USD 43.78 billion in 2025, with a CAGR of 7.49%, reaching USD 62.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 40.77 billion
Estimated Year [2025] USD 43.78 billion
Forecast Year [2030] USD 62.90 billion
CAGR (%) 7.49%

Pioneering a New Era in Non-Opioid Therapeutics through Advanced Molecular Targets, Patient-Centric Solutions, and Collaborative Innovation to Transform Pain Management

The evolution of pain management is undergoing a fundamental shift as non-opioid therapeutics ascend to the forefront of medical innovation. This surge is rooted in the convergence of advanced molecular research, patient-centered care models, and a global regulatory environment that prioritizes safety and efficacy. By moving beyond traditional opioid reliance, the industry is opening avenues for novel therapeutic modalities that promise to reduce dependency risks while maintaining robust clinical outcomes.

As a result, stakeholders across the value chain are collaborating to harness the potential of targeted small molecules, biologics, and innovative drug delivery systems. These efforts reflect a broad commitment to addressing chronic pain, inflammatory disorders, and neurodegenerative conditions with modalities that can offer comparable relief to opioids but with enhanced safety profiles. Moreover, advancements in biomarkers and genomics are enabling more personalized treatment strategies, aligning with the growing demand for precision medicine.

Consequently, the non-opioid therapeutics sector is positioned for a transformative trajectory. From early-stage research to late-phase clinical trials, the integration of cross-disciplinary expertise is driving accelerated innovation. As this introductory analysis establishes, the industry's renewed focus on collaborative research, regulatory alignment, and patient wellbeing lays a solid foundation for sustained growth and long-term impact.

Unveiling the Transformative Shifts Redefining the Non-Opioid Therapeutics Landscape with Emerging Modalities, Regulatory Realignments, and Digital Health Integration

The current landscape of non-opioid therapeutics is being reshaped by transformative shifts that encompass emerging modalities, regulatory realignments, and technology integration. For instance, the rise of next-generation ion channel modulators and peptide-based therapies is redefining the pharmacological toolkit. In parallel, regulatory bodies in key markets have issued updated guidelines that streamline expedited pathways for therapies demonstrating favorable safety margins compared to controlled substances.

Furthermore, digital health applications and remote monitoring platforms are enhancing treatment adherence and enabling real-time patient feedback, which, in turn, inform continuous improvement in therapeutic protocols. This digital infusion is complementing pharmacological advances by facilitating more nuanced patient engagement and outcome measurement. As a result, healthcare providers are increasingly adopting integrated care models that bridge pharmacotherapy with digital support services.

In addition, strategic alliances between academic institutions, mid-sized biotechnology firms, and contract research organizations are accelerating preclinical to clinical transitions. By leveraging shared resources and multidisciplinary expertise, these collaborations are reducing development timelines while maintaining rigorous scientific validation. These collective initiatives are driving the paradigm shift from opioid-centric pain management toward diversified, non-addictive therapeutic approaches.

Analyzing the Comprehensive Impact of the 2025 United States Tariffs on Non-Opioid Therapeutics Supply Chains, Pricing Structures, and Global Trade Dynamics

The introduction of the 2025 United States tariffs has exerted significant pressure on the global supply chains underpinning non-opioid therapeutic development and distribution. Manufacturers reliant on imported active pharmaceutical ingredients have faced elevated procurement costs, prompting a reevaluation of supplier relationships and nearshoring strategies. In response, several mid-sized producers have initiated localized sourcing agreements to safeguard continuity and cost predictability.

Meanwhile, pricing structures throughout the distribution network have adjusted to reflect the altered cost base, affecting both contract negotiations with large health systems and procurement practices at retail outlets. This shift has underscored the importance of dynamic pricing strategies that balance margin protection with accessibility for end users. Consequently, organizations are deploying advanced analytics to model tariff pass-through scenarios and to optimize channel-specific pricing architectures.

Concurrently, global trade dynamics have prompted companies to diversify manufacturing footprints across multiple jurisdictions. Establishing secondary production nodes in regions with favorable trade agreements has mitigated exposure to unilateral tariff increases. As a result, resilience planning now occupies a central role in strategic roadmaps, ensuring that the non-opioid therapeutics sector remains agile amid evolving geopolitical landscapes.

Deriving Key Insights from Drug Type, Administration Route, Clinical Application, End Use, and Distribution Channel to Map the Non-Opioid Therapeutics Market Landscape

Insights derived from drug type segmentation reveal that acetaminophen derivatives remain a cornerstone for acute pain relief, while advancements in antidepressant mechanisms are unlocking new pathways for chronic pain modulation. Parallel developments in antiepileptics are showing promise for neuropathic pain management, and innovations in local anesthetics are enhancing perioperative care. Nonsteroidal anti-inflammatory drugs continue to serve a broad spectrum of inflammatory indications, with next-generation formulations improving gastrointestinal tolerability.

When evaluating route of administration and application segments, the intravenous channel has gained traction for rapid-onset interventions in hospital settings, whereas oral therapies offer convenience and adherence in chronic care scenarios. Rectal delivery, though less prominent, persists as an alternative for patients requiring non-oral dosing. In terms of clinical focus, cancer related pain management is benefitting from multimodal regimens that integrate pharmacological and supportive therapies. Chronic pain protocols are evolving with combination approaches that leverage centrally acting agents. Inflammatory disorders, migraine relief, and neurodegenerative pain syndromes are all seeing targeted therapeutic designs informed by enhanced pathophysiological understanding.

Examining end use and distribution channels underscores the growing role of ambulatory surgical centers and diagnostic centers in outpatient pain management. Home care settings are expanding as telehealth-enabled nursing services provide continuous support. Hospitals and clinics remain critical for acute intervention. Meanwhile, hospital pharmacies lead in dispensing specialized non-opioid formulations. Online pharmacies are driving accessibility for maintenance therapies, and retail pharmacies continue to serve as the primary point of contact for over-the-counter anti-inflammatory and analgesic products.

Exploring Distinct Regional Dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific Shaping Market Penetration, Patient Access, and Growth Opportunities

In the Americas, regulatory agencies have harmonized approval processes to prioritize therapeutics demonstrating non-addictive profiles, fostering robust clinical pipelines and encouraging venture capital investment. Healthcare reimbursement models are increasingly accommodating non-opioid alternatives, and patient advocacy groups are influencing policy to expand access to innovative therapies. This regional momentum is accelerating product launches and creating a fertile ground for pilot programs in integrated pain management.

Across Europe, the Middle East & Africa, stakeholders face a diverse tapestry of regulatory frameworks and reimbursement structures. In Western Europe, strong pharmacovigilance measures and centralized approval systems are driving the adoption of novel compounds. Meanwhile, in select Middle Eastern and African markets, growing demand for cost-effective non-opioid options is inspiring local manufacturing initiatives. Cross-border collaborations and public-private partnerships are critical in addressing infrastructure gaps and streamlining distribution pathways.

The Asia-Pacific region is witnessing rapid growth underpinned by rising healthcare expenditure and expanding hospital networks. Regulatory authorities in key markets have introduced fast-track designations for therapies addressing opioid dependence. Additionally, digital health ecosystems are maturing, enabling better patient monitoring and adherence tracking. Regional manufacturing clusters are also emerging as strategic export hubs, further integrating Asia-Pacific into global supply chains.

Illuminating Leading Industry Players and Innovative Partnerships Driving Research, Development, and Commercialization in the Non-Opioid Therapeutics Sector

Leading industry players are adopting multifaceted strategies to maintain competitive advantage in the non-opioid therapeutics arena. Global pharmaceutical companies with extensive R&D capabilities are expanding their portfolios through internal discovery programs and targeted acquisitions of biotech innovators. At the same time, dedicated non-opioid specialists are forging partnerships with academic centers and contract research organizations to accelerate translational research.

Beyond traditional pharma, technology-driven start-ups are integrating digital biomarkers and artificial intelligence to optimize dosing regimens and predict patient response. This convergence of software and pharmacology is redefining value propositions and enabling more nuanced differentiation among therapeutic candidates. In parallel, manufacturing service providers are investing in flexible production platforms capable of handling peptide-based therapies and other complex molecules, thereby meeting the evolving demands of their pharmaceutical clients.

Collectively, these strategic movements underscore a sectorwide commitment to innovation, quality, and patient-centric outcomes. Enhanced collaboration between established players and nimble innovators is catalyzing a synergistic ecosystem where each participant contributes unique expertise toward the shared goal of delivering effective non-opioid solutions.

Presenting Strategic, Actionable Recommendations for Industry Leaders to Enhance Collaboration, Accelerate Innovation, and Navigate Regulatory Complexities in Non-Opioid Therapeutics

Industry leaders should prioritize strategic alliances that bridge academic research with commercial development to accelerate pipeline progression. By leveraging shared expertise and resource pools, organizations can mitigate early-stage risks and enhance candidate validation. Simultaneously, forming consortia that advocate for harmonized regulatory standards will streamline approval pathways and reduce time to market.

Investing in advanced analytics and digital health solutions is another critical recommendation. Implementing real-world evidence platforms will enable continuous post-launch monitoring of safety and efficacy, thereby reinforcing stakeholder confidence. Moreover, integrating patient engagement tools can improve adherence rates and inform iterative product enhancements.

Supply chain resilience must remain a focal point. To this end, diversifying sourcing strategies and establishing backup manufacturing nodes will minimize the disruptive impact of geopolitical shifts and tariff fluctuations. Finally, fostering a culture of cross-functional collaboration-uniting R&D, regulatory affairs, commercial teams, and patient advocacy groups-will ensure that therapeutic offerings are aligned with evolving clinical needs and market dynamics.

Detailing the Comprehensive Multi-Source Research Methodology Underpinning the Market Analysis, Incorporating Primary Interviews, Secondary Data Validation, and Expert Panel Reviews

This analysis is underpinned by a robust, multi-phase research methodology combining primary and secondary data sources. Primary research involved in-depth interviews with senior executives across pharmaceutical, biotechnology, and healthcare provider organizations, alongside discussions with regulatory experts and key opinion leaders to validate emerging trends and strategic priorities.

Secondary research encompassed a comprehensive review of peer-reviewed journals, conference proceedings, patent filings, regulatory agency publications, and industry whitepapers to build a foundational understanding of technological, clinical, and policy developments. Data triangulation techniques were employed to ensure consistency and accuracy across disparate information streams.

Expert panel reviews provided additional validation, enabling refinement of thematic insights and strategic imperatives. Quantitative and qualitative findings were synthesized to produce a nuanced, evidence-based narrative that reflects both macro-level dynamics and granular operational considerations.

Concluding Remarks Emphasizing the Transformative Potential of Non-Opioid Therapeutics to Meet Unmet Needs, Drive Sustainable Growth, and Improve Patient Outcomes Globally

The journey toward widespread adoption of non-opioid therapeutics is marked by innovation, strategic collaboration, and evolving regulatory landscapes. As stakeholders align around the shared imperative to reduce opioid dependency, the sector is witnessing an unprecedented surge in novel molecular entities, digital health integrations, and patient-centric care models.

Regional dynamics and tariff implications underscore the need for adaptive strategies that balance cost resilience with market expansion. Segmentation insights reveal targeted opportunities across drug types, administration routes, clinical applications, and distribution channels. Leading companies are leveraging partnerships, technological capabilities, and manufacturing flexibility to capture these opportunities, while actionable recommendations emphasize the importance of cross-functional collaboration and advanced analytics.

Ultimately, the non-opioid therapeutics sector is poised to transform pain management paradigms and improve patient outcomes globally. By harnessing these insights, industry participants can make informed decisions that drive meaningful progress and sustainable growth in this critical therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emergence of topical anti inflammatory formulations utilizing next generation liposomal delivery systems for localized pain control
  • 5.2. Expansion of novel sodium channel blockers for chronic neuropathic pain management in aging populations
  • 5.3. Regulatory fast track approvals encouraging development of novel cholecystokinin receptor modulators for post operative pain relief
  • 5.4. Integration of virtual reality and digital therapeutics for non opioid pain treatment across rehabilitation settings
  • 5.5. Adoption of transcriptome-based biomarkers to personalize non opioid analgesic therapies and improve clinical outcomes
  • 5.6. Rising investment in monoclonal antibodies targeting nerve growth factor for osteoarthritis and lower back pain relief
  • 5.7. Strategic partnerships between biotech and digital health firms to accelerate non opioid pain management solutions

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Non-Opioid Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Acetaminophen
  • 8.3. Antidepressants
  • 8.4. Antiepileptics
  • 8.5. Local Anesthetics
  • 8.6. Nonsteroidal Anti-Inflammatory Drugs

9. Non-Opioid Therapeutics Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Rectal

10. Non-Opioid Therapeutics Market, by Application

  • 10.1. Introduction
  • 10.2. Cancer Related Pain
  • 10.3. Chronic Pain
  • 10.4. Inflammatory Disorders
  • 10.5. Migraine
  • 10.6. Neurodegenerative Disorders

11. Non-Opioid Therapeutics Market, by End Use

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Centers
  • 11.4. Home Care Settings
  • 11.5. Hospitals & Clinics

12. Non-Opioid Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Non-Opioid Therapeutics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Non-Opioid Therapeutics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Non-Opioid Therapeutics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Acorda Therapeutics, Inc.
    • 16.3.4. Allay Therapeutics Inc.
    • 16.3.5. Alnylam Pharmaceuticals, Inc.
    • 16.3.6. Biogen Inc.
    • 16.3.7. Centrexion Therapeutics,
    • 16.3.8. Concentric Analgesics, Inc.
    • 16.3.9. Confo Therapeutics NV
    • 16.3.10. Durect Corporation
    • 16.3.11. Eli Lilly and Company
    • 16.3.12. Latigo Biotherapeutics, Inc.
    • 16.3.13. Lexicon Pharmaceuticals, Inc.
    • 16.3.14. Liquidia Corporation
    • 16.3.15. McNeil-PPC, Inc. by Johnson & Johnson Inc.
    • 16.3.16. Mylan N.V. by Viatris Inc.
    • 16.3.17. Neumentum Inc.
    • 16.3.18. SiteOne Therapeutics, Inc.
    • 16.3.19. Sun Pharmaceutical Industries Limited
    • 16.3.20. Tris Pharma, Inc.
    • 16.3.21. Vertex Pharmaceuticals Incorporated
    • 16.3.22. Pfizer Inc.
    • 16.3.23. Amgen Inc.
    • 16.3.24. Cara Therapeutics, Inc.
    • 16.3.25. Bioelectronics Corporation

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. NON-OPIOID THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. NON-OPIOID THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. NON-OPIOID THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. NON-OPIOID THERAPEUTICS MARKET: RESEARCHAI
  • FIGURE 26. NON-OPIOID THERAPEUTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. NON-OPIOID THERAPEUTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. NON-OPIOID THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NON-OPIOID THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CANCER RELATED PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CANCER RELATED PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY MIGRAINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 85. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 87. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 89. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 90. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 93. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 96. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 97. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 99. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 100. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 101. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 103. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 107. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 109. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 110. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 111. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 113. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 117. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 119. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 120. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 121. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 145. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 149. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 152. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 153. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 155. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 159. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 162. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 163. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 165. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 169. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 171. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 172. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 173. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 175. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 179. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 181. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 182. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 183. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 185. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 192. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 193. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 212. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 213. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 219. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 221. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 222. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 223. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 229. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 231. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 232. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 233. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 242. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 245. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 249. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 252. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 253. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 259. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 261. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 262. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 263. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 265. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 269. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 271. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 272. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 273. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 275. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 279. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 281. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 283. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 285. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 292. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 293. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 295. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 299. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 301. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 302. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 303. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 305. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 307. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 309. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 311. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 313. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 315. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 319. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 321. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 322. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 323. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIST